Open access · CC-BY
via OpenAlex
Safety of beta‐nicotinamide mononucleotide (β‐NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC
Novel Foods and Food Allergens (NDA) EFSA Panel on Nutrition, Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline J. M. Castenmiller, Stefaan De Henauw, Angeles M. Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige A. McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank L. Thies, Margarita Aguilera‐Gómez
EFSA Journal · 2026 · ▲ 1 citations
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on beta-nicotinamide mononucleotide (β-NMN) as a novel food (NF) pursuant to Regulation (EU) 2015/2283, including an evaluation of the safety of its use in food supplements as a source of niacin, and the bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. The NF consists of chemically synthesised β-NMN and is intended for use in food supplements as a source of niacin up to 300 mg/day. The target population is adults, excluding pregnant and lactating women. The identity, production process, composition and specifications of the NF do not raise safety concerns. A human intervention study comparing the relative bioavailability of β-NMN and nicotinamide in equimolar amounts supported the use of a conversion factor (CF) of 1. On this basis, the proposed maximum intake corresponds to 109.7 mg/day of nicotinamide. This amount is approximately five times the population reference intake (PRI) of niacin for adults but remains below the upper level (UL) of 900 mg/day for nicotinamide. No concerns were identified regarding genotoxicity. In a 90-day repeated dose oral toxicity study in rats, effect on reproductive organs were observed and the no observed adverse effect level (NOAEL) of 400 mg/kg bw per day identified, resulting in a margin of exposure (MoE) of 93. The available human study did not raise safety concerns. Based on the nature and the metabolic fate of the NF, the proposed use levels and the available human data, the calculated MoE was considered sufficient. The Panel concludes that the NF is safe under the proposed conditions of use for the adult population, excluding pregnant and lactating women and that the NF constitutes a bioavailable source of nicotinamide, a form of niacin.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.2903/j.efsa.2026.10007
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Nutrition, N.F.A.F.A.(.E.P.O., Turck, D., Bohn, T., Cámara, M., Castenmiller, J.J.M., Henauw, S.D., Jos, A.M., Maciuk, A., Mangelsdorf, I., McNulty, B.A., Naska, A., Pentieva, K., Siani, A., Thies, F.L., Aguilera‐Gómez, M., Cubadda, F., Frenzel, T., Gundert‐Remy, U., Marcon, F., & McArdle, H.J. (2026). Safety of beta‐nicotinamide mononucleotide (β‐NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC. <em>EFSA Journal</em>. https://doi.org/10.2903/j.efsa.2026.10007
Vancouver
Nutrition NFAFA(EPO, Turck D, Bohn T, Cámara M, Castenmiller JJM, Henauw SD, et al. Safety of beta‐nicotinamide mononucleotide (β‐NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC. EFSA Journal. 2026. doi:10.2903/j.efsa.2026.10007.
BibTeX
@article{novel2026Safety,
title = {Safety of beta‐nicotinamide mononucleotide (β‐NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC},
author = {Novel Foods and Food Allergens (NDA) EFSA Panel on Nutrition and Dominique Turck and Torsten Bohn and Montaña Cámara and Jacqueline J. M. Castenmiller and Stefaan De Henauw and Angeles M. Jos and Alexandre Maciuk and Inge Mangelsdorf and Breige A. McNulty and Androniki Naska and Kristina Pentieva and Alfonso Siani and Frank L. Thies and Margarita Aguilera‐Gómez and Francesco Cubadda and Thomas Frenzel and Ursula Gundert‐Remy and Francesca Marcon and Harry J McArdle and Monika Neuhäuser‐Berthold and Miguel Prieto Maradona and Alexandros Siskos and Matthew Wright and Elisa Beneventi},
journal = {EFSA Journal},
year = {2026},
doi = {10.2903/j.efsa.2026.10007},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
EFSA Journal 2019
Open access · CC-BY
Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC
EFSA Journal 2021
Open access · CC-BY
Extension of use of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283
Medicine & Science in Sports & Exercise 2022
Citation only
Urolithin A, A Gut Microbiome Derived Compound Improves Mitochondrial Health And Muscle Performance
The Journal of Clinical Endocrinology & Metabolism 2015
Open access · CC-BY
α-Klotho Expression in Human Tissues
Journal of applied physiology (Bethesda, Md. : 1985) 2026
Citation only
Anthracycline chemotherapy does not increase arterial stiffness or carotid intima-media thickness in young adult survivors of hematological malignancies.
Nature Communications 2021
Open access · CC-BY